Paclitaxel Accord Healthcare Italia 6 mg/ml

DRUG2 trials

Sponsors

Fondazione Ricerca Traslazionale, Istituto Di Ricerche Farmacologiche Mario Negri

Conditions

HER2-negativebreast carcinomaestrogen receptor–positiveneoadjuvant chemotherapystage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)stage II–IIIB

Phase 2

Neoadjuvant chemo-immunotherapy for stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)

RecruitingCTIS2024-519205-35-01

Fondazione Ricerca Traslazionalestage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)

Start: 2025-07-08Target: 30Updated: 2025-09-10

A Pragmatic Phase II Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2− Early Breast Cancer Using Oncotype DX and Abemaciclib - VIOLET trial

Not yet recruitingCTIS2026-525457-37-00

Istituto Di Ricerche Farmacologiche Mario NegriHER2-negative, stage II–IIIB, neoadjuvant chemotherapy +2

Target: 150Updated: 2026-10-16